Warm autoantibody, two units needed, and a resident who wants to skip the workup
A 58-year-old woman with a bleeding duodenal ulcer has a haemoglobin of 5.9 g/dL and is haemodynamically borderline. The antibody screen is positive with a panagglutinin. The direct antiglobulin test is positive for IgG and C3d, and the eluate reacts with all panel cells. She was transfused two years ago at another hospital and has had two prior pregnancies. The blood bank has no record of her previous red cell phenotype, and no historical sample is available. Two units are needed urgently, and the emergency department is asking for O-negative red cells. A junior resident suggests that the antibody screen can be ignored because 'this is just autoimmune haemolytic anaemia'.
1. Interpret the serology. Which findings support warm autoimmune haemolysis, and what must still be excluded before the resident's suggestion is acted on?
Read the worked answer
Supporting warm AIHA: a panreactive antibody screen, a positive DAT for IgG (with or without C3d), and a panreactive eluate together form the classic triad. The C3d component may also reflect a cold autoantibody or complement activation and should not be dismissed.
Why the resident is wrong - while the conclusion may still be to transfuse:
- A panagglutinin masks an underlying alloantibody. A warm autoantibody plus an anti-E, anti-K or anti-Jka looks exactly like a simple autoantibody until adsorption is done.
- She has had two pregnancies and a transfusion, so alloimmunisation is plausible.
- An antibody against a high-incidence antigen (e.g. anti-Vel, anti-Tja, anti-Lan) can present as panreactivity and is the classic cause of a fatal haemolytic reaction when ignored.
Workup, in parallel with clinical care:
- Phenotype the patient's cells (Rh, Kell, Duffy, Kidd, MNS); if the autoantibody blocks the reagents, genotype for RH variants and KEL.
- Allogeneic adsorption with three phenotyped alloadsorbing cells, then re-test the adsorbed serum. Autologous adsorption is possible in principle after two years, but the autoantibody may not adsorb completely.
- Re-run the screen, panel and DAT with a different technique (gel versus tube) and a pre-warmed technique to exclude a cold component.
- Exclude drug-induced haemolysis and a delayed haemolytic transfusion reaction.
2. Two units are required now. How do you select the units, and how do you monitor the transfusion?
Read the worked answer
Do not delay transfusion for a serological workup, and do not skip the workup either. The two decisions are independent.
Unit selection:
- Once the alloadsorption has been interpreted, select ABO-compatible units that are antigen-negative for any identified alloantibody, and phenotype-matched for Rh and Kell where feasible.
- If no truly compatible unit exists, issue 'least incompatible' units - the ones with the weakest reaction strength by the same technique - and say so explicitly on the label and in the record.
- O-negative uncrossmatched units are for exsanguinating haemorrhage, which this is not; routine use wastes a scarce resource and deprives the patient of phenotype matching.
- Use leucodepleted units to reduce further alloimmunisation and febrile reactions.
Monitoring:
- Transfuse slowly with vital signs at 15 minutes and hourly; watch for fever, loin pain, dark urine and falling blood pressure.
- Check a post-transfusion sample for a falling DAT and repeat the antibody screen at 2–4 weeks, when the autoantibody may have receded and any alloantibody will be easier to detect.
- Expect an attenuated haemoglobin increment; do not interpret a poor increment as evidence of a further alloantibody without repeating the serology.
- Warn the clinical team about the risk of hyperhaemolysis, which can occur even with apparently matched units.
3. What must the final report and the communication with the clinical team contain?
Read the worked answer
The report should be structured around what is known, what has been excluded and what remains uncertain:
- Serological findings: panreactive screen, IgG + C3d DAT, panreactive eluate.
- Adsorption results and the conclusion - for example 'allogeneic adsorption reveals no underlying alloantibody' or 'anti-E identified after adsorption'.
- Phenotype or genotype, and whether the phenotype was determined serologically or inferred molecularly.
- A clear statement of residual risk if the adsorption was incomplete or the patient has been transfused within the last three months.
- Transfusion recommendation and the units issued, with reaction strengths.
Communication to the clinical team:
- The diagnosis of warm AIHA does not remove the need for antigen-matched units.
- A medical alert card or equivalent record must be given to the patient, and the antibody history must be entered into the hospital and regional transfusion databases.
- A pre-transfusion sample should be retained for future reference; the next laboratory will need it.
- Clinical teams must report any reaction promptly, and repeat serology at 2–4 weeks should be booked before discharge.
Document the resident's request and its refusal with reasons. That note protects the patient and the blood bank, and it is also the teaching moment.